Oct 11, 2005

Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats

Critical Care Medicine
Takeshi SuzukiJunzo Takeda


Since beta-blocker therapy is known to be effective in patients with an injured heart, such as infarction, we designed the present study to examine the protective effects of infusion of the beta1-selective blocker esmolol on myocardial function in peritonitis-induced septic rats using an isolated working heart preparation. Randomized animal study. University research laboratory. Thirty-one rats treated with cecal ligation and perforation to evoke peritonitis. After cecal ligation and perforation, rats were randomly allocated to the control group (normal saline 2 mL/hr, n = 11), low-dose esmolol group (10 mg/kg/hr, n = 10), or high-dose esmolol group (20 mg/kg/hr, n = 10). After obtaining blood samples for measurement of arterial lactate and tumor necrosis factor-alpha at 24 hrs, we assessed cardiac output, myocardial oxygen consumption, and cardiac efficiency (cardiac output x peak systolic pressure/myocardial oxygen consumption) at various preloads in an isolated perfused heart preparation. Esmolol infusion did not cause an elevation of arterial lactate levels but reduced tumor necrosis factor-alpha concentrations vs. the control group (p < .05). Both cardiac output and cardiac efficiency in the esmolol-treated rats were signi...Continue Reading

  • References33
  • Citations53

Mentioned in this Paper

Tumor Necrosis Factor-alpha
Normal saline
D-lactate Measurement
Myocardial Dysfunction
beta-Adrenergic Blocker [EPC]
Lactic Acid Measurement

Related Feeds


Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.